SUTRO BIOPHARMA, INC. Shareholders' Equity
SUTRO BIOPHARMA, INC. (STRO) had Shareholders' Equity of -$103.32 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-12
- 2026-06-30: Stockholders' Equity Attributable to Parent -$103.32M.
- 2026-03-31: Stockholders' Equity Attributable to Parent -$66.89M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$132.45M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$87.27M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | -$103.32M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | -$66.89M 10-Q · filed 2026-08-12 | |
| 2025-12-31 | -$132.45M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | -$87.27M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | -$32.11M 10-Q · filed 2026-08-12 | |
| 2025-03-31 | -$25.81M 10-Q · filed 2026-08-12 | |
| 2024-12-31 | $44.60M 10-Q · filed 2026-08-12 | |
| 2024-09-30 | $111.22M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $152.18M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $98.02M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $149.65M 10-K · filed 2026-03-23 | |
| 2023-09-30 | $112.43M 10-Q · filed 2024-11-13 | $112.35M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $154.72M 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $185.41M 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $217.05M 10-K · filed 2025-03-13 | |
| 2022-09-30 | $229.73M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $209.06M 10-Q · filed 2023-11-13 | |
| 2022-03-31 | $220.37M 10-Q · filed 2023-11-13 | |
| 2021-12-31 | $252.56M 10-K · filed 2025-03-13 | |
| 2021-09-30 | $283.58M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $307.50M 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $307.34M 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $332.05M 10-K · filed 2024-03-25 | |
| 2020-09-30 | $244.12M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $206.76M 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $82.08M 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $97.79M 10-K · filed 2023-03-30 | |
| 2019-09-30 | $109.91M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $119.56M 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $130.72M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $131.54M 10-K · filed 2022-02-28 | |
| 2018-09-30 | -$141.43M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | -$132.02M 10-Q · filed 2019-11-08 | |
| 2018-03-31 | -$120.75M 10-Q · filed 2019-11-08 | |
| 2017-12-31 | -$109.00M 10-K · filed 2021-03-18 | |
| 2016-12-31 | -$90.90M 10-K · filed 2020-03-16 | |
| 2015-12-31 | -$93.90M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |